about
Tumor Targeting and Drug Delivery by Anthrax ToxinNanotheranostics for personalized medicinePolymer nanostructures synthesized by controlled living polymerization for tumor-targeted drug deliveryGlobal substrate profiling of proteases in human neutrophil extracellular traps reveals consensus motif predominantly contributed by elastaseXTEN as Biological Alternative to PEGylation Allows Complete Expression of a Protease-Activatable Killin-Based CytostaticThe Proteasix OntologySupramolecular Crafting of Self-Assembling Camptothecin Prodrugs with Enhanced Efficacy against Primary Cancer CellsConstructing de novo H2O2 signaling via induced protein proximityAcquisition of accurate data from intramolecular quenched fluorescence protease assays.Protease-Sensitive Nanomaterials for Cancer Therapeutics and Imaging.Real-time monitoring of caspase cascade activation in living cellsNoninvasive monitoring of pulmonary fibrosis by targeting matrix metalloproteinases (MMPs).Rational design of matrix metalloproteinase-13 activatable probes for enhanced specificity.The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer.Prodrug applications for targeted cancer therapy.A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivosym-Triazines for directed multitarget modulation of cholinesterases and amyloid-β in Alzheimer's disease.Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug TherapyProtease activity: meeting its theranostic potentialProtease substrate profiling using bacterial display of self-blocking affinity proteins and flow-cytometric sorting.Ras transformation results in cleavage of reticulon protein Nogo-B that is associated with impairment of IFN responseOptical imaging of tumor microenvironmentTargeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.Synthesis and in vitro efficacy of MMP9-activated NanoDendrons.Utilizing the Multiradionuclide Resolving Power of SPECT and Dual Radiolabeled Single Molecules to Assess Treatment Response of Tumors.Synthesis and Preclinical Evaluation of a Highly Improved Anticancer Prodrug Activated by Histone Deacetylases and Cathepsin L.Molecular imaging with engineered physiology.Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell CarcinomaMSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition.Basics and recent advances in peptide and protein drug delivery.Targeting kallikrein-related peptidases in prostate cancer.Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases.Matrix metalloproteinases as reagents for cell isolation.Diagnosing peri-implant disease using the tongue as a 24/7 detectorAbdominal aortic aneurysms targeted by functionalized polysaccharide microparticles: a new tool for SPECT imaging.Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.The rational design of a gemcitabine prodrug with AIE-based intracellular light-up characteristics for selective suppression of pancreatic cancer cells.Peptide-drug conjugates as effective prodrug strategies for targeted delivery.Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.KLK-targeted Therapies for Prostate Cancer.
P2860
Q26744720-1AB38BA2-E3B8-4C1B-9100-9EE92AF80886Q26851449-66623255-2BF4-4F22-A846-C40C387243B2Q28085664-68388C4E-9E7F-48C9-BF1C-B7447946A2CDQ28533695-92AD02B3-F7BD-4712-8572-A4FFBFF451C3Q28550226-307A4296-BB7A-49A1-9EBE-03A3D2E32E23Q28829147-5816C229-9890-46BD-8C60-6F067F6F7C86Q28833661-08F1BC55-6A63-49D4-BCDD-F8D195D0DEC3Q28833835-1F7EAE7C-B0E3-4A1D-AB21-513DD8BE2799Q30274929-5AF1EF3A-C934-4D49-BD78-60E68F668B77Q30355600-1E749485-F2A3-433D-A57D-D2C6614CA42FQ30525436-3139744A-09E4-44DA-AAFF-FC3F6BA2AFB5Q30540289-7836FF0F-744C-4BDE-82D7-69953ABF96EDQ30573504-06D7AB6A-D6C6-4E52-83D3-5BCE067FFEEAQ33720126-8B0E80DD-59D0-4D69-BD0E-40FE79D6BA8EQ34099780-329904B0-1D96-4E9B-9841-AE11A65E7BD0Q34491149-ABCDD741-E78A-40A1-851C-6874580338ACQ34591673-0380EB78-1EEC-4DC7-B360-8DD35A732F75Q35662216-778A8E9A-252E-4E34-B59E-046DC1F6DA5EQ35811497-683A6022-8F96-41B0-B779-C39612B684CBQ36174822-23DC5D69-5036-400F-94EE-362D75BEFA80Q36188447-DB2C9170-7EC8-4719-887D-F26395D60F02Q36533809-ED26FCC7-4908-473D-A853-80DD84A00EAEQ36545204-C4678F05-3D92-41B4-84C1-49A8FCE72D83Q36775887-84444DEC-9A6A-4B69-A764-402496EF7E73Q36858394-E9635C64-B561-4C55-BC27-465771341404Q36882948-80E5384B-4993-4DA3-8C09-465ED224C17EQ37486959-493DD1A9-ABBF-4E8A-BEC0-D5EFEF411A29Q37559487-99253572-96A6-491A-A1C2-34232B639014Q38154210-1EA46E86-A596-4C4A-B744-7A611E66F279Q38162494-3CA536BD-B1D3-45B2-902F-58190979F0EDQ38191293-51A3BF96-CB57-4490-A4B5-904E9E06C0B3Q38222628-B9AEEBC1-687C-4212-B6C2-5B54F2305DEEQ38435741-ABD5030C-BAE2-48AC-95EF-4745C70DE81DQ38641983-B8600501-62BD-4782-9593-4BB58215DFBFQ38688674-E25811CF-EED8-4865-8478-28008EE243F3Q38760061-39D8BD35-4A00-432A-9D28-78AF0AEB5DE3Q38827817-2CCF7B78-0E0D-4248-BB44-87A815F959B8Q38883760-25FCDDE8-FB11-4E8E-849C-25D9C257F592Q38898249-649E3477-B741-4B25-84B4-FB3088D66824Q38967486-34C669F7-BB96-4498-B596-B0D83210925E
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Protease-activated drug development.
@ast
Protease-activated drug development.
@en
type
label
Protease-activated drug development.
@ast
Protease-activated drug development.
@en
prefLabel
Protease-activated drug development.
@ast
Protease-activated drug development.
@en
P2860
P50
P356
P1433
P1476
Protease-activated drug development.
@en
P2093
Ki Young Choi
P2860
P304
P356
10.7150/THNO.4068
P577
2012-02-08T00:00:00Z